Details of the Drug Transporter (DTP)

General Information of Drug Transporter (DTP) (ID: DTZRMK5)

DTP Name Multidrug resistance protein 3 (ABCB4)
Gene Name ABCB4
UniProt ID
P21439 (MDR3_HUMAN)
VARIDT ID
DTD0013
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Synonyms ABC21; ABCB4; ATP-binding cassette sub-family B member 4; GBD1; ICP3; MDR2; MDR2/3; MDR3; P-glycoprotein 3; PFIC-3; PGY3; Phosphatidylcholine translocator ABCB4
DTP Family ATP-Binding Cassette (ABC) Superfamily
Multidrug Resistance Exporter (MDR) Family (ABCB)
Sequence
MDLEAAKNGTAWRPTSAEGDFELGISSKQKRKKTKTVKMIGVLTLFRYSDWQDKLFMSLG
TIMAIAHGSGLPLMMIVFGEMTDKFVDTAGNFSFPVNFSLSLLNPGKILEEEMTRYAYYY
SGLGAGVLVAAYIQVSFWTLAAGRQIRKIRQKFFHAILRQEIGWFDINDTTELNTRLTDD
ISKISEGIGDKVGMFFQAVATFFAGFIVGFIRGWKLTLVIMAISPILGLSAAVWAKILSA
FSDKELAAYAKAGAVAEEALGAIRTVIAFGGQNKELERYQKHLENAKEIGIKKAISANIS
MGIAFLLIYASYALAFWYGSTLVISKEYTIGNAMTVFFSILIGAFSVGQAAPCIDAFANA
RGAAYVIFDIIDNNPKIDSFSERGHKPDSIKGNLEFNDVHFSYPSRANVKILKGLNLKVQ
SGQTVALVGSSGCGKSTTVQLIQRLYDPDEGTINIDGQDIRNFNVNYLREIIGVVSQEPV
LFSTTIAENICYGRGNVTMDEIKKAVKEANAYEFIMKLPQKFDTLVGERGAQLSGGQKQR
IAIARALVRNPKILLLDEATSALDTESEAEVQAALDKAREGRTTIVIAHRLSTVRNADVI
AGFEDGVIVEQGSHSELMKKEGVYFKLVNMQTSGSQIQSEEFELNDEKAATRMAPNGWKS
RLFRHSTQKNLKNSQMCQKSLDVETDGLEANVPPVSFLKVLKLNKTEWPYFVVGTVCAIA
NGGLQPAFSVIFSEIIAIFGPGDDAVKQQKCNIFSLIFLFLGIISFFTFFLQGFTFGKAG
EILTRRLRSMAFKAMLRQDMSWFDDHKNSTGALSTRLATDAAQVQGATGTRLALIAQNIA
NLGTGIIISFIYGWQLTLLLLAVVPIIAVSGIVEMKLLAGNAKRDKKELEAAGKIATEAI
ENIRTVVSLTQERKFESMYVEKLYGPYRNSVQKAHIYGITFSISQAFMYFSYAGCFRFGA
YLIVNGHMRFRDVILVFSAIVFGAVALGHASSFAPDYAKAKLSAAHLFMLFERQPLIDSY
SEEGLKPDKFEGNITFNEVVFNYPTRANVPVLQGLSLEVKKGQTLALVGSSGCGKSTVVQ
LLERFYDPLAGTVFVDFGFQLLDGQEAKKLNVQWLRAQLGIVSQEPILFDCSIAENIAYG
DNSRVVSQDEIVSAAKAANIHPFIETLPHKYETRVGDKGTQLSGGQKQRIAIARALIRQP
QILLLDEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEH
GTHQQLLAQKGIYFSMVSVQAGTQNL
Function
This energy-dependent phospholipid efflux translocator that acts as a positive regulator of biliary lipid secretion. And it as a floppase that translocates specifically phosphatidylcholine (PC) from the inner to the outer leaflet of the canalicular membrane bilayer into the canaliculi of hepatocytes. It indirectly involved in cholesterol efflux activity from hepatocytes into the canalicular lumen in the presence of bile salts in an ATP-dependent manner. In cooperation with ATP8B1, functions to protect hepatocytes from the deleterious detergent activity of bile salts.
Endogenous Substrate(s) Phosphatidylcholine; Short-chain fatty acids
TCDB ID
3.A.1.201.3
Gene ID
5244
KEGG Pathway
ABC transporters (hsa02010 )
Bile secretion (hsa04976 )
Reactome Pathway
ABC-family proteins mediated transport (R-HSA-382556 )
Defective ABCB4 causes PFIC3, ICP3 and GBD1 (R-HSA-5678771 )
PPARA activates gene expression (R-HSA-1989781 )

Molecular Interaction Atlas (MIA) of This DTP

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTP
5 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Digoxin DMQCTIH Arrhythmia BC9Z Approved [6]
Paclitaxel DMLB81S Breast carcinoma Approved [6]
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [7]
Verapamil DMA7PEW Angina pectoris BA40 Approved [6]
Vinblastine DM5TVS3 Advanced cancer 2A00-2F9Z Approved [6]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTP

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTP
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 1.40E-17 -2.88E-01 -9.34E-01
Adrenocortical carcinoma 2D11.Z Kidney 1.97E-01 -3.89E-01 -6.41E-01
Alopecia ED70 Skin from scalp 8.49E-05 3.15E-01 7.62E-01
Alzheimer's disease 8A20 Entorhinal cortex 5.97E-02 -2.65E-02 -2.02E-01
Ankylosing spondylitis FA92.0 Pheripheral blood 4.31E-01 1.86E-01 4.19E-01
Aortic stenosis BB70 Calcified aortic valve 7.38E-01 2.02E-01 6.77E-01
Apnea 7A40 Hyperplastic tonsil 3.19E-01 3.54E-01 7.14E+00
Arthropathy FA00-FA5Z Peripheral blood 4.62E-01 -1.43E-01 -3.97E-01
Asthma CA23 Nasal and bronchial airway 4.04E-01 5.68E-02 1.47E-01
Atopic dermatitis EA80 Skin 4.01E-05 -2.78E-01 -9.97E-01
Autism 6A02 Whole blood 7.88E-01 -8.32E-02 -1.64E-01
Autoimmune uveitis 9A96 Peripheral monocyte 6.67E-01 -1.22E-01 -4.40E-01
Autosomal dominant monocytopenia 4B04 Whole blood 8.07E-01 -3.83E-02 -2.81E-01
Bacterial infection of gingival 1C1H Gingival tissue 9.04E-01 2.00E-02 9.65E-02
Batten disease 5C56.1 Whole blood 3.82E-01 5.54E-01 1.22E+00
Behcet's disease 4A62 Peripheral blood 5.94E-01 -2.04E-01 -6.37E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 7.03E-01 2.12E-03 1.89E-02
Bladder cancer 2C94 Bladder tissue 6.04E-06 -4.15E-01 -4.20E+00
Breast cancer 2C60-2C6Z Breast tissue 2.06E-16 1.04E-01 4.99E-01
Cardioembolic stroke 8B11.20 Whole blood 4.77E-07 -1.03E+00 -1.71E+00
Cervical cancer 2C77 Cervical tissue 3.75E-01 -3.52E-02 -2.31E-01
Childhood onset rheumatic disease FA20.Z Peripheral blood 8.34E-01 -1.88E-01 -2.31E-01
Chronic hepatitis C 1E51.1 Whole blood 6.79E-01 -2.56E-03 -1.23E-02
Chronic obstructive pulmonary disease CA22 Lung tissue 1.41E-01 5.99E-02 3.73E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 8.29E-02 8.51E-03 7.53E-02
Chronic rhinosinusitis CA0A Sinus mucosa tissue 1.90E-01 7.04E-02 7.99E-01
Colon cancer 2B90 Colon tissue 2.67E-05 -1.40E-01 -6.15E-01
Coronary artery disease BA80-BA8Z Peripheral blood 2.34E-01 -3.83E-01 -8.67E-01
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 9.13E-01 2.57E-01 4.42E-01
Endometriosis GA10 Endometrium tissue 4.36E-01 -3.83E-03 -8.26E-03
Familial hypercholesterolemia 5C80.00 Peripheral blood 1.91E-01 -9.59E-02 -5.69E-01
Familial hypercholesterolemia 5C80.00 Whole blood 1.78E-04 -3.75E-01 -1.69E+00
Gastric cancer 2B72 Gastric tissue 8.77E-01 -1.50E-02 -6.83E-02
Glioblastopma 2A00.00 Nervous tissue 3.32E-129 4.96E-01 2.02E+00
Glioma 2A00.0Y-2A00.0Z White matter tissue 2.08E-01 -1.40E-01 -1.44E-01
Head and neck cancer 2D42 Head and neck tissue 2.12E-01 1.07E-01 1.73E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 5.46E-01 -3.98E-02 -2.97E-01
Huntington's disease 8A01.10 Whole blood 7.61E-01 2.05E-02 1.10E-01
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 2.00E-02 2.38E-01 1.80E+00
Immunodeficiency 4A00-4A20 Peripheral blood 9.22E-01 -3.24E-02 -2.33E-01
Influenza 1.00E+30 Whole blood 6.13E-02 1.07E-01 1.31E+00
Interstitial cystitis GC00.3 Bladder tissue 1.56E-02 5.30E-01 3.36E+00
Intracranial aneurysm 8B01.0 Intracranial artery 1.06E-04 -6.41E-01 -2.06E+00
Irritable bowel syndrome DD91.0 Rectal colon tissue 8.71E-01 -2.35E-02 -5.04E-02
Ischemic stroke 8B11 Peripheral blood 4.98E-01 4.67E-02 1.72E-01
Juvenile idiopathic arthritis FA24 Peripheral blood 4.92E-02 8.20E-02 1.34E-01
Lateral sclerosis 8B60.4 Cervical spinal cord 5.89E-01 2.78E-02 1.39E-01
Lateral sclerosis 8B60.4 Skin 9.80E-01 -4.84E-02 -2.27E-01
Liver cancer 2C12.0 Liver tissue 1.10E-09 -7.72E-01 -8.24E-01
Liver failure DB99.7-DB99.8 Liver tissue 1.26E-02 -3.19E+00 -4.57E+00
Lung cancer 2C25 Lung tissue 5.70E-30 2.08E-01 8.96E-01
Lupus erythematosus 4A40 Whole blood 1.07E-02 -4.40E-01 -3.18E-01
Major depressive disorder 6A70-6A7Z Whole blood 1.33E-01 -1.50E-01 -2.95E-01
Major depressive disorder 6A70-6A7Z Hippocampus 9.66E-01 -6.64E-02 -5.69E-01
Melanoma 2C30 Skin 2.78E-01 1.20E-01 1.38E-01
Multiple myeloma 2A83.1 Bone marrow 1.61E-02 1.55E-02 1.40E-01
Multiple myeloma 2A83.1 Peripheral blood 8.51E-01 -9.37E-03 -1.00E-01
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 2.18E-01 2.61E-01 1.12E+00
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 7.47E-01 -8.91E-02 -4.28E-01
Myelofibrosis 2A20.2 Whole blood 1.00E-03 -4.46E-01 -2.55E+00
Myocardial infarction BA41-BA50 Peripheral blood 8.28E-01 -1.89E-01 -2.36E-01
Myopathy 8C70.6 Muscle tissue 1.20E-02 -5.21E-01 -1.34E+00
Neonatal sepsis KA60 Whole blood 8.55E-12 -6.39E-01 -1.05E+00
Neuroectodermal tumour 2A00.11 Brain stem tissue 1.65E-05 2.53E-01 1.18E+00
Non-alcoholic fatty liver disease DB92 Liver tissue 7.02E-01 1.52E-01 1.57E-01
Obesity related type 2 diabetes 5A11 Omental adipose tissue 1.99E-01 8.03E-02 4.97E-01
Olive pollen allergy CA08.00 Peripheral blood 9.74E-01 -1.82E-01 -3.33E-01
Oral cancer 2B6E Oral tissue 1.98E-02 -1.39E-01 -2.37E-01
Osteoarthritis FA00-FA0Z Synovial tissue 1.28E-02 -5.95E-01 -1.31E+00
Osteoporosis FB83.1 Bone marrow 3.81E-01 4.27E-01 4.89E-01
Ovarian cancer 2C73 Ovarian tissue 1.52E-01 -9.05E-02 -1.45E-01
Pancreatic cancer 2C10 Pancreas 5.82E-01 2.02E-01 2.24E-01
Parkinson's disease 8A00.0 Substantia nigra tissue 3.61E-01 4.25E-02 4.18E-01
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 4.37E-03 -5.30E-01 -9.54E-01
Pituitary cancer 2D12 Pituitary tissue 5.79E-03 1.89E-01 9.10E-01
Pituitary gonadotrope tumour 2D12 Pituitary tissue 3.38E-02 2.04E-01 1.04E+00
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 8.79E-01 1.28E-02 8.39E-02
Polycythemia vera 2A20.4 Whole blood 8.96E-09 -2.51E-01 -1.36E+00
Pompe disease 5C51.3 Biceps muscle 6.87E-03 -6.94E-01 -1.05E+00
Preterm birth KA21.4Z Myometrium 3.13E-01 -1.76E-01 -1.66E+00
Prostate cancer 2C82 Prostate 1.44E-03 2.19E-01 6.39E-01
Psoriasis EA90 Skin 1.59E-01 1.19E-02 2.88E-02
Rectal cancer 2B92 Rectal colon tissue 2.52E-01 -1.03E-01 -1.13E+00
Renal cancer 2C90-2C91 Kidney 2.43E-06 4.02E-01 1.69E+00
Retinoblastoma 2D02.2 Uvea 6.66E-03 4.41E-01 3.14E+00
Rheumatoid arthritis FA20 Synovial tissue 5.20E-03 -8.34E-01 -1.71E+00
Rhinovirus infection CA42.1 Nasal epithelium tissue 1.19E-01 2.76E-02 3.06E-01
Schizophrenia 6A20 Prefrontal cortex 7.79E-02 2.76E-02 5.72E-02
Schizophrenia 6A20 Superior temporal cortex 7.76E-01 -6.69E-03 -6.66E-02
Scleroderma 4A42.Z Whole blood 4.15E-03 -8.30E-01 -1.63E+00
Seizure 8A60-8A6Z Whole blood 9.85E-01 -1.74E-01 -2.22E-01
Sensitive skin EK0Z Skin 8.53E-01 -1.22E-01 -1.13E+00
Sepsis with septic shock 1G41 Whole blood 1.13E-32 -7.32E-01 -1.34E+00
Shwachman-Diamond syndrome 3A70.0 Bone marrow 2.47E-02 -9.50E-01 -1.52E+00
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 5.24E-01 -2.02E-01 -5.99E-01
Simpson golabi behmel syndrome LD2C Adipose tissue 7.02E-01 1.16E-02 8.84E-02
Sjogren's syndrome 4A43.2 Salivary gland tissue 1.17E-01 1.07E-01 1.30E+00
Skin cancer 2C30-2C3Z Skin 1.38E-11 1.83E-01 4.02E-01
Thrombocythemia 3B63 Whole blood 5.03E-01 -2.41E-03 -1.24E-02
Thrombocytopenia 3B64 Whole blood 8.44E-01 -2.91E-01 -5.46E-01
Thyroid cancer 2D10 Thyroid 1.76E-01 1.03E-01 2.18E-01
Tibial muscular dystrophy 8C75 Muscle tissue 6.81E-07 -1.61E+00 -2.47E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 2.79E-02 2.13E-01 3.76E+00
Type 2 diabetes 5A11 Liver tissue 9.41E-01 5.89E-02 1.75E-01
Ureter cancer 2C92 Urothelium 1.88E-01 -2.84E-01 -5.83E-01
Uterine cancer 2C78 Endometrium tissue 3.94E-03 5.13E-02 2.38E-01
Vitiligo ED63.0 Skin 9.34E-01 1.36E-01 2.51E-01
------------------------------------------------------------------------------------
⏷ Show the Full List of Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DTP

DTP DTT Name Multidrug resistance protein 3 (ABCB4) DTT Info
DTP DTT Type Clinical trial
1 Clinical Trial Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Encequidar DMM8Z3Q Metastatic breast cancer 2C6Y Phase 2 [1]
------------------------------------------------------------------------------------
4 Discontinued Drug(s) Targeting This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dofequidar fumarate DMWMHU7 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 3 [2]
LY335979 DM2KITF Acute myeloid leukaemia 2A60 Discontinued in Phase 3 [3]
Dexniguldipine DMLZIT2 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [4]
LANIQUIDAR DM3YABD Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [5]
------------------------------------------------------------------------------------

References

1 Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor. J Med Chem. 2021 Apr 8;64(7):3677-3693.
2 Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol. 1995;35(4):271-7.
3 A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxoru... Clin Cancer Res. 2004 May 15;10(10):3265-72.
4 Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol. 1995 Mar 1;49(5):603-9.
5 Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9.
6 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
7 Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.